Results 51 to 60 of about 5,389 (186)

Pharmacokinetic Drug–Drug Interaction Potential of Oral Anticancer Drugs

Clinical Pharmacology &Therapeutics, EarlyView.
Drug–drug interaction (DDI) management is critical for safe and effective use of oral anticancer drugs (OADs). Our study objectives were to (i) compile clinically relevant pharmacokinetic (PK) DDI mechanisms for OADs and (ii) assess the prevalence of PK potential DDIs (PDDIs) in patients with advanced solid cancers.
Fatimah Alhurayri, Islam R. Younis, Shadia I. Jalal, Theodore F. Logan, Rohan Maniar, Steven M. Bray, Sara K. Quinney, Zeruesenay Desta, Todd C. Skaar, James E. Tisdale, Tyler Shugg   +10 more
wiley   +1 more source

A Phase Ib/II Study of WNT974 + Encorafenib + Cetuximab in Patients With BRAF V600E-Mutant KRAS Wild-Type Metastatic Colorectal Cancer [PDF]

, 2023
Cetuximab; Colorectal cancer; MetastaticCetuximab; Càncer de còlon; MetastàticCetuximab; Cáncer de colon; MetastásicoBackground WNT974 is a small molecule inhibitor of Wnt signaling that specifically inhibits porcupine O-acyltransferase.
de Braud, Filippo Guglielmo Maria, Elez, Elena, GARRALDA, Elena, Geva, Ravit, Tabernero, Josep, Tai, David, Van Cutsem, Eric   +6 more
core   +1 more source

Systemic anti‐cancer therapy associated with the occurrence of peripheral neurotoxicity and, specifically, peripheral neuropathy

International Journal of Cancer, EarlyView.
What's New? While the effectiveness of systemic anticancer therapy is well documented, it commonly causes severe toxicity. This study of the 467 systemic anticancer therapy agents currently approved globally for clinical and/or research purposes found that peripheral neurotoxicity is associated with 45% of classical chemotherapies, 21% of targeted ...
Cassie Higgins, Lynn R. Gauthier, Blair H. Smith, Lesley Colvin   +3 more
wiley   +1 more source

Mapping genetic interactions in cancer: a road to rational combination therapies. [PDF]

, 2019
The discovery of synthetic lethal interactions between poly (ADP-ribose) polymerase (PARP) inhibitors and BRCA genes, which are involved in homologous recombination, led to the approval of PARP inhibition as a monotherapy for patients with BRCA1/2 ...
Krogan, Nevan J, Tutuncuoglu, Beril
core  

European expert panel consensus on the clinical management of BRAFV600E-mutant metastatic colorectal cancer [PDF]

, 2023
Consensus; Metastatic colorectal cancer; TreatmentConsens; Càncer colorectal metastàtic; TractamentConsenso; Cáncer colorrectal metastásico; TratamientoMetastatic colorectal cancer (mCRC) is a heterogenous disease caused by various genetic alterations ...
Arnold, Dirk, Cervantes, Andrés, Martinelli, Erika, Stintzing, Sebastian, Tabernero Caturla, Josep, Van Cutsem, Eric   +5 more
core   +1 more source

Impact of non‐genetic heterogeneity of BRAF‐mutant colon cancer organoids on growth kinetics, drug sensitivity and Wnt dynamics

International Journal of Cancer, EarlyView.
What's New? Patient‐derived organoids (PDOs) model tumor biology and drug response while preserving key tumor features, yet the impact of non‐genetic culture variables is poorly understood. This study examined the influence of organoid size, seeding density, and morphology on growth, drug sensitivity, and Wnt signaling in a colorectal cancer organoid ...
Viktoria Zieger, Ellen Woehr, Jasmin Traichel, Tilman Brummer, Roland Zengerle, Sabrina Kartmann, Stefan Zimmermann   +6 more
wiley   +1 more source

Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated BRAF V600E–Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study [PDF]

, 2021
PURPOSE: BEACON CRC evaluated encorafenib plus cetuximab with or without binimetinib versus investigators' choice of irinotecan or FOLFIRI plus cetuximab in patients with BRAFV600E-mutant metastatic colorectal cancer (mCRC), after progression on 1-2 ...
Arkenau, H-T, Christy-Bittel, J, Ciardiello, F, Desai, J, Elez, E, Garcia-Alfonso, P, Gollerkeri, A, Grothey, A, Guren, TK, Hong, YS, Kopetz, S, Loupakis, F, Maharry, K, Steeghs, N, Tabernero, J, Van Cutsem, E, Wasan, H, Yaeger, R, Yoshino, T   +18 more
core   +1 more source

A phase II study of daily encorafenib in combination with biweekly cetuximab in patients with BRAF V600E mutated metastatic colorectal cancer: the NEW BEACON study

BMC Cancer, 2022
Background Patients with BRAF V600E mutated metastatic colorectal cancer (mCRC) have a poor prognosis. The introduction of BRAF targeted therapy with encorafenib and weekly administered cetuximab have shown improved survival with a median progression ...
Martina Eriksen, Per Pfeiffer, Kristoffer Staal Rohrberg, Christina Westmose Yde, Lone Nørgård Petersen, Laurids Østergaard Poulsen, Camilla Qvortrup   +6 more
doaj   +1 more source

Identification of BRAF V600E Mutation in Cerebrospinal Fluid Aids in Diagnosing Leptomeningeal Carcinomatosis Arising From Pleomorphic Xanthoastrocytoma: A Case Report

Cancer Reports, Volume 9, Issue 3, March 2026.
ABSTRACT Background Pleomorphic xanthoastrocytomas (PXAs) are rare primary central nervous system (CNS) tumors that appear heterogeneous on imaging and histology and typically cause headaches or seizures on initial presentation. Alongside high rates of favorable prognosis after surgical excision exist similarly high rates of recurrence.
Randy S. D'Amico, Patricia Avancena, Alon Kashanian, Rosivel Galvez, Deborah Gruber, Sami Saba, Avraham Zlochower, Manju Harshan, Morana Vojnic   +8 more
wiley   +1 more source

BRAF V600E-mutant colorectal cancer with CNS metastases treated successfully with encorafenib, binimetinib and cetuximab

CNS Oncology
This report describes a case of BRAF V600E-mutated colorectal cancer with CNS metastases in which treatment with encorafenib, binimetinib and cetuximab was effective.
Toru Imai, Hirokazu Shoji, Hidekazu Hirano, Kunihito Matsuguma, Takahito Awatsu, Toshiharu Hirose, Natsuko Okita, Atsuo Takashima, Ken Kato   +8 more
doaj   +1 more source